Clinical trial · Observational
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aim of the study: The main aim is to collect data of patients with lung cancer, and to perform different analyses on this data. The data contains information on patient and tumor characteristics, imaging, and treatment characteristics. With this data it is possible to improve and validate the predictive model for survival and long term toxicity in lung cancer by multicentric prospective data collection. The long term aim, beyond this specific study, is to build a Decision Support System based on the predictive models validated in this study. Hypothesis: The general hypothesis is that we get a better prediction in terms of AUC (area under the curve) of survival and long term toxicity when we combine multifactorial variables. These variables consist of information from clinical data, imaging data, data related to treatment type and treatment quality.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (6)
- label
- 1: Surgery alone or combined with (chemo)radiotherapy
- description
- * Fresh frozen tumor tissue and normal tissue; * Recording of clinical characteristics, imaging, surgery features. After treatment: FU at 2-3 weeks post surgery, 3,6,12,24 and 36 months post-surgery
- label
- 2: Radiotherapy alone
- description
- (including stereotactic radiotherapy) * Before start RT (during staging):Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes; * Day 0 (before start RT): Recording of clinical characteristics, imaging, and radiotherapy features; * Day 8-12 (during RT): Scoring of toxicity. After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT
- label
- 3: Sequential chemotherapy and radiotherapy
- description
- * Day -30 (before start CT): * Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes; * Recording of clinical characteristics, imaging, and chemotherapy features. * Day 0 (before start RT): * Recording of clinical characteristics, imaging, and radiotherapy features. * Scoring of toxicity. * Day 8-12 (during RT): * Scoring of toxicity. After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological proven lung cancer (small cell or non-small cell); * 18 years or older; * Informed consent according to national rules (US: written informed consent, NL: no objection rule)
References
Publications (0)
Data not yet available